Table 2.
Studies on using chemotherapy alone.
| Author | N | Type of malignancy | Treatment regimen | Response | Study design |
|---|---|---|---|---|---|
| Shoji et al..24 | 26 (advanced ampullar carcinoma n=12, recurrent ampullary cancer n=14) | Ampullary Carcinoma | 5-FU based vs Gemcitabine based | Median OS 9.1 months. Median progression free survival 3.2 months | Retrospective |
| Senatore et al.27 | na | Ampullary Carcinoma | 5-FU based | Good response | Case report |
| Kim HS et al..25 | 21 | Recurrent or metastatic Ampullary Carcinoma | Capecitabine + Oxaliplatin | Median OS 19.7 months Median TTP 7.6 months | Retrospective |
| Overman et al.26 | 30 | Ampullary+ Small bowel carcinoma | Capecitabine+ Oxaliplatin | Median OS 20.4 months. Median TTP 11.3 months | Phase II |
| Nassour et al.28 | 880 | Ampullary Carcinoma | Na | Median OS 47.2 months Good response | Retrospective |
| Neoptolemos et | 428 | Ampullary+ Bileduct+ other cancers | 5-FU and Gemcitabine groups | Median OS 43.1 months | Phase III RCT |
| Kim ST et al.30 | 29 | Ampullary Carcinoma | Cisplatin+ Gemcitabine/ 5-FU/Capecitabine | Median OS 12.5 months Median TTP 4.9 months | Phase II |
| Cereda et al.31 | 37 | Biliary tract+ Ampullary Carcinoma | Cisplatin+ Epirubicin+ Gemcitabine+ 5-FU. | Median OS 12.1 months Median PFS 7.9 months | Phase II |
| Andre et al.32 | 56 | Biliary tract + Ampullary Carcinoma | Gemcitabine + Oxaliplatin | Median OS 7.6-15.4 months | Phase II |
| Gibson et al.33 | 38 | Small Bowel+ Ampullary Carcinoma | 5FU+Doxorubicin+ Mitomycin | Median OS 8 months. | Phase II |
| Valle et al.34 | 410 | Biliary tract + Ampullary Carcinoma | Gemcitabine+ Cisplatin | Median OS 11.7 months. | Phase III |